Vanda Pharmaceuticals (VNDA) Invested Capital (2009 - 2026)

Vanda Pharmaceuticals has disclosed Invested Capital across 18 years of filings, most recently posting $280.8 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $280.8 million, down 45.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $280.8 million (down 45.1% YoY), and the FY2025 annual result was $334.7 million, down 38.42% from the prior year.
• Invested Capital came in at $280.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $334.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $544.9 million in Q4 2023 to a low of $280.8 million in Q1 2026.
• The 5-year median for Invested Capital is $527.2 million (2022), against an average of $498.1 million.
• Across the five-year window, Invested Capital advanced 7.38% in 2022 and tumbled 45.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Invested Capital stood at $527.2 million in 2022, then rose by 3.36% to $544.9 million in 2023, then declined by 0.26% to $543.5 million in 2024, then plunged by 38.42% to $334.7 million in 2025, then fell by 16.11% to $280.8 million in 2026.
• The last three Invested Capital figures came in at $280.8 million (Q1 2026), $334.7 million (Q4 2025), and $466.0 million (Q3 2025), per Business Quant data.